3.2 Prior Authorization Criteria & Clinical Documentation Requirements

3.2 Prior Authorization Criteria & Clinical Documentation Requirements

Prior Authorization (PA) is a formal utilization management process requiring the prescribing clinician and pharmacy to obtain advance approval from a health plan or Pharmacy Benefit Manager (PBM) before a specific medication can be dispensed under the pharmacy benefit. When a prescription requires prior authorization, submitting an electronic claim without prior payer approval triggers NCPDP Reject 75 (Prior Authorization Required).

To secure PA approval, the healthcare team must demonstrate that the prescribed therapy meets explicit, evidence-based clinical criteria established by the plan's Pharmacy and Therapeutics (P&T) committee. For pharmacy technicians, understanding the required clinical documentation, diagnostic validation standards, and regulatory review timelines is vital to prevent care interruptions and avoid claim denials.

+-----------------------------------------------------------------------------+
|                     THE THREE PILLARS OF PRIOR AUTHORIZATION                |
|                                                                             |
|   1. PATIENT SAFETY & APPROPRIATENESS                                       |
|      - Monitors contraindications, black box warnings, and drug interactions|
|      - Verifies patient demographics and organ function thresholds          |
|                                                                             |
|   2. EVIDENCE-BASED INDICATION ALIGNMENT                                    |
|      - Validates ICD-10 diagnosis against FDA labels and medical compendia  |
|      - Confirms disease staging and objective clinical biomarkers           |
|                                                                             |
|   3. COST CONTAINMENT & FINANCIAL STEWARDSHIP                               |
|      - Ensures lower-cost, equally effective therapies are tried first     |
|      - Protects health plan reserves and patient benefit longevity          |
+-----------------------------------------------------------------------------+

---

1. Clinical & Economic Objectives of Prior Authorization

Prior authorization is not merely an administrative hurdle; it serves critical clinical, safety, and economic functions within the healthcare system:

1. Patient Safety & Risk Mitigation

• High-risk therapeutics—such as biologics, immunosuppressants, direct-acting antivirals, and controlled substances—carry significant risks of organ toxicity, severe infections, or drug-drug interactions.
• PA protocols verify baseline organ function (renal/hepatic panels), screen for latent infections (e.g., tuberculosis screening prior to anti-TNF biologic initiation), and confirm adherence to mandatory Risk Evaluation and Mitigation Strategies (REMS) programs.

2. Clinical Appropriateness & Compendia Alignment

• Verifies that the medication is prescribed for a medically accepted indication supported by FDA labeling or recognized drug compendia, including:
  • AHFS Drug Information (AHFS-DI)
  • Micromedex (DrugPoints System)
  • National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (standard for oncology indications)
• Curbs improper off-label prescribing lacking robust, peer-reviewed clinical evidence.

3. Cost Containment & Stewardship

• Specialty and biologic therapies frequently cost between $5,000 and $100,000+ per month. PA criteria ensure these high-cost agents are reserved for patients with confirmed clinical need who have not achieved adequate therapeutic control with established, cost-effective first-line agents.

---

2. Core Clinical Documentation Requirements

To evaluate a PA request, PBM clinical reviewers require objective medical evidence. Generic attestations (e.g., checking a box stating "patient failed alternatives") are systematically rejected. The documentation packet must contain five core components:

+-----------------------------------------------------------------------------+
|                   ANATOMY OF A COMPLETE PA CLINICAL PACKET                  |
|                                                                             |
|   [1. CLINICAL CHART NOTES]   -> Detailed physician progress notes          |
|   [2. ICD-10 DIAGNOSIS]       -> Exact coding to highest specificity        |
|   [3. OBJECTIVE LAB VALUES]   -> Baseline labs, viral loads, biomarkers     |
|   [4. TRIAL & FAILURE RECORD] -> Drug names, doses, dates, adverse reactions|
|   [5. PRESCRIBER SPECIALTY]   -> Alignment with disease specialty board     |
+-----------------------------------------------------------------------------+

1. Comprehensive Prescriber Chart Notes

• Must include formal clinical progress notes from recent office visits (typically within the last 60 to 90 days).
• Must detail the patient's complete medical history, physical examination findings, documented symptom severity, functional impairment scores (e.g., Crohn's Disease Activity Index [CDAI], Expanded Disability Status Scale [EDSS] for multiple sclerosis), and current treatment strategy.

2. ICD-10-CM Diagnosis Code Specificity

• Claims and PA submissions must include the exact ICD-10-CM diagnosis code mapped to the highest level of clinical specificity.
• General or unspecified codes (e.g., M25.50 - Pain in unspecified joint) trigger immediate administrative denials. Specific codes (e.g., M05.79 - Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement) are mandatory.

3. Objective Laboratory & Diagnostic Biomarkers

Many PA guidelines require quantitative baseline laboratory values demonstrating disease severity or organ safety:

---

4. Comprehensive Trial & Failure Documentation

When a plan requires prior trial and failure of formulary preferred alternatives, the clinical packet must furnish specific historical data for each attempted agent:

1. Exact Medication Identifier: Specific generic and brand name.
2. Dosage & Administration Route: Specific strength, daily dose, and dosage form (e.g., "Metformin 1,000 mg PO BID"). Sub-therapeutic dosages do not satisfy trial requirements.
3. Duration of Therapy: Exact start and discontinuation dates verifying an adequate therapeutic duration (e.g., minimum 8 to 12 consecutive weeks of compliance).
4. Objective Clinical Outcome:
   • Therapeutic Failure: Documented clinical lack of efficacy (e.g., "HbA1c remained $8.8%$ after 12 weeks of maximally tolerated metformin").
   • Intolerable Adverse Reaction: Explicit documentation of severe adverse drug events (e.g., "Severe intractable lactic acidosis or refractory gastrointestinal toxicity requiring discontinuation").
   • Documented Contraindication: Recognized medical contraindications (e.g., "Severe chronic kidney disease with eGFR $< 30 \text{ mL/min}/1.73\text{ m}^2$").

5. Prescriber Specialty Alignment

Many PBM clinical policies mandate that high-cost specialty medications be prescribed by, or in formal written consultation with, a board-certified specialist in the relevant clinical field:

• Rheumatology: Mandated for anti-TNF biologics, JAK inhibitors, and IL-6/IL-17 antagonists for rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
• Oncology / Hematology: Mandated for oral antineoplastics and targeted kinase inhibitors.
• Dermatology: Mandated for biologics treating severe plaque psoriasis, hidradenitis suppurativa, or atopic dermatitis.
• Neurology: Mandated for disease-modifying therapies for multiple sclerosis, CGRP antagonists for refractory migraine, or ALS therapeutics.
• Gastroenterology: Mandated for advanced biologics for Crohn's disease and ulcerative colitis.

[!IMPORTANT] Prescriber Validation Rule: If a primary care physician (PCP) writes a prescription for a restricted specialty biologic without documented specialist co-management, the PA will be denied for failure to satisfy prescriber taxonomy criteria. The technician must confirm that the specialist's Type 1 NPI is referenced in the submission packet.

---

3. Regulatory Review Turnaround Standards

Turnaround times for prior authorization reviews are strictly regulated under federal CMS Medicare Part D regulations, state insurance department mandates, and National Committee for Quality Assurance (NCQA) accreditation benchmarks.

+-----------------------------------------------------------------------------+
|                 PRIOR AUTHORIZATION REVIEW TURNAROUND MATRIX                |
|                                                                             |
|   [STANDARD REVIEW]                                                         |
|   - Statutory Maximum: Up to 72 Hours (3 Calendar Days)                     |
|   - Applies to routine maintenance and non-urgent therapy                   |
|   - Clock begins upon receipt of complete clinical information              |
|                                                                             |
|   [EXPEDITED / URGENT REVIEW]                                               |
|   - Statutory Maximum: Within 24 Hours (1 Calendar Day)                     |
|   - Applies when delay jeopardizes life, health, or ability to regain funct.|
|   - Mandated if patient suffers from severe, unbearable acute pain          |
+-----------------------------------------------------------------------------+

Standard Review Turnaround Standard

• Timeline: The health plan or PBM must render a coverage determination and notify both the prescriber and the enrollee within 72 hours (3 calendar days) of receiving the completed PA request.
• Scope: Applies to routine chronic maintenance medications, non-urgent dose escalations, and elective therapies.

Expedited (Urgent) Review Turnaround Standard

• Timeline: The health plan must render a determination and deliver verbal and written notification within 24 hours (1 calendar day).
• Statutory Criteria for Expedited Review: An expedited review is legally mandated when applying the standard 72-hour timeframe could:
  1. Seriously jeopardize the patient's life or physical/mental health.
  2. Seriously jeopardize the patient's ability to regain maximum functional capacity.
  3. Subject the patient to severe, unbearable pain that cannot be adequately managed without the requested drug.
• Physician Attestation: If a licensed physician certifies that the expedited criteria are met, the health plan cannot downgrade the request to standard review.

---

4. Pharmacy Technician's Role in PA Coordination

Pharmacy technicians serve as critical coordinators in the prior authorization lifecycle:

+-----------------------------------------------------------------------------+
|                      TECHNICIAN PA OPERATIONAL WORKFLOW                     |
|                                                                             |
|   [Step 1] Detect NCPDP Reject 75 at POS Adjudication                       |
|   [Step 2] Identify Plan BIN/PCN & Retrieve Specific PA Form/Portal         |
|   [Step 3] Forward PA Request & Criteria Checklist to Prescriber Clinic     |
|   [Step 4] Track Submission Status & Payer Adjudication Clocks              |
|   [Step 5] Input Authorization # upon Approval & Re-adjudicate Claim        |
+-----------------------------------------------------------------------------+

1. Rejection Identification: Recognizing NCPDP Reject 75 and distinguishing whether the rejection requires a standard PA, a step therapy exception, or a quantity limit override.
2. Payer Criteria Retrieval: Accessing the PBM's provider portal or electronic clearinghouse to pull the exact clinical questionnaire and criteria worksheet for the requested drug.
3. Prescriber Notification: Transmitting the PA request, rejection details, and required clinical criteria checklist directly to the prescriber's clinical team via secure electronic portals or integrated EHR queues.
4. Tracking & Timeline Monitoring: Monitoring the 24-hour expedited or 72-hour standard review clocks, ensuring missing documentation requests from the PBM are resolved immediately.
5. Re-adjudication & Claim Completion: Once approved, recording the authorization number, effective date range, and approved quantity into the Pharmacy Management System (PMS) and re-submitting the claim for paid adjudication.